IN VIVO TUMOR MODELS FOR CANCER IMMUNOTHERAPY

ONCOLOGY

Oncology is an area that commands a larger proportion of the research world's resources. Porsolt is now able to provide services using its Oncology in vitro capabilities and expertise.

IN VIVO TUMOR MODELS FOR CANCER IMMUNOTHERAPY

In recent years, a number of immune checkpoint inhibitors have been granted FDA approval. Although efficient, monoclonal antibodies targeting immune checkpoints have been found to produce objective and durable anti-tumor response in a limited number of cancer patients. To identify novel therapeutic strategies capable of enhancing the efficacy of immune checkpoint inhibitors, Porsolt offers validated syngeneic mouse tumor model of anti-CTLA-4 and anti-PD-L1 immunotherapies.­­

PREDICTIVE IN VIVO MODELS OF ANTI-CTLA-4 & ANTI-PD-L1 CANCER IMMUNOTHERAPIES

  • Syngeneic tumor models: to closely recapitulate tumor-immune system interactions, tumor cells are inoculated into immunocompetent mice.
  • A well-characterized colorectal cancer model of immune checkpoint blockade, which responds to CTLA-4 inhibition but not to anti-PD-L1 immunotherapy

ASSESSMENT OF ANTI-TUMOR EFFICACY AND IMMUNE RESPONSE PROFILE

  • Preclinical efficacy study: Experimental groups (N=8-10) are monitored 3 times per week. Readouts include tumor size, survival and body weight.
  • Immune response assessment: satellite mice are added to each group for immune profiling at the tumor site or in peripheral compartments (spleen, lymph nodes) by flow cytometry or high-content imaging.

PORSOLT'S ADDED VALUE

  • Fast study initiation and weekly reports: syngeneic tumor models are set up and ready for treatment within 15 to 20 days after proposal validation. Preliminary reports are then are communicated every week.
  • Validated markers of immune response: CD4, CD8, CD25, FOXP3, CD11b, Gr1, CD11c, mPDCA1...
  • RTq-PCR analysis for immune-related genes: Il6, Ifng, Il17, Tnfa, Tgfb, Il10, Foxp3, Rorgt, Cd274 (PD-L1), Pdcd1 (PD1), …